Product Name
ATP13A2, siRNA
Full Product Name
ATP13A2 siRNA (Human)
Product Synonym Names
PARK9; Probable cation-transporting ATPase 13A2
Product Gene Name
ATP13A2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9NQ11
Specificity
ATP13A2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human ATP13A2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of ATP13A2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
ATP13A2 sirna
siRNA to inhibit ATP13A2 expression using RNA interference
Applications Tested/Suitable for ATP13A2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for ATP13A2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001135445.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001141973.2
[Other Products]
UniProt Primary Accession #
Q9NQ11
[Other Products]
UniProt Secondary Accession #
O75700; Q5JXY1; Q5JXY2; Q6S9Z9[Other Products]
UniProt Related Accession #
Q9NQ11[Other Products]
Molecular Weight
128,323 Da
NCBI Official Full Name
probable cation-transporting ATPase 13A2 isoform 2
NCBI Official Synonym Full Names
ATPase type 13A2
NCBI Official Symbol
ATP13A2??[Similar Products]
NCBI Official Synonym Symbols
CLN12; KRPPD; PARK9; HSA9947
??[Similar Products]
NCBI Protein Information
probable cation-transporting ATPase 13A2
UniProt Protein Name
Probable cation-transporting ATPase 13A2
Protein Family
Probable cation-transporting ATPase
UniProt Gene Name
ATP13A2??[Similar Products]
UniProt Synonym Gene Names
PARK9??[Similar Products]
UniProt Entry Name
AT132_HUMAN
NCBI Summary for ATP13A2
This gene encodes a member of the P5 subfamily of ATPases which transports inorganic cations as well as other substrates. Mutations in this gene are associated with Kufor-Rakeb syndrome (KRS), also referred to as Parkinson disease 9. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2008]
UniProt Comments for ATP13A2
ATP13A2: May play a role in intracellular cation homeostasis and the maintenance of neuronal integrity. Expressed in brain; protein levels are markedly increased in brain from subjects with Parkinson disease and subjects with dementia with Lewy bodies. Detected in pyramidal neurons located throughout the cingulate cortex. In the substantia nigra, it is found in neuromelanin- positive dopaminergic neurons. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type V subfamily. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: Hydrolase; Transporter, ion channel; Membrane protein, integral; EC 3.6.3.-; Transporter; Membrane protein, multi-pass
Chromosomal Location of Human Ortholog: 1p36
Cellular Component: lysosomal membrane; lysosome; integral to membrane
Molecular Function: protein binding; metal ion binding; ATPase activity; ATP binding
Biological Process: metabolic process; cation transport
Disease: Kufor-rakeb Syndrome
Research Articles on ATP13A2
1. A review of recent advances in the emerging association of ATP13A2 mutations with Parkinsonism and neuronal ceroid lipofuscinoses.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
